Mutation in the Methylenetetrahydrofolate Reductase Gene Is Not Associated With Increased Risk for Coronary Artery Disease or Myocardial Infarction

Objectives. We sought to determine whether the C677T transition in the methylenetetrahydrofolate reductase (MTHFR) gene is associated with increased risk for coronary artery disease (CAD) or myocardial infarction (MI). Background. Elevated plasm homocysteine has been identified as risk factor for coronary atherosclerosis. Homocysteinemi may result from deficient MTHFR activity. thermolabile form of MTHFR, associated with C677T genetic transition, shows reduced activity and may be risk factor for CAD. Methods. Blood was withdrawn from patients undergoing coronary angiography, and DN was extracted by phenol-chloroform method. Genotyping was done by polymerase chain reaction (PCR) amplification of 198-base pair segment of the MTHFR gene that brackets nucleotide 677. The amplicon was digested with the HinfI restriction enzyme. Products were visualized after electrophoresis in 1.5% agarose with ethidium bromide. Results. Among 200 patients with diagnosis of MI, the polymorphic allelic frequency was 33.3%, compared with 32.1% among 554 control subjects (p = 0.68); homozygosity was present in 11.5% of patients and 10.6% of control subjects (p = 0.74, odds ratio [OR] 1.09, 95% confidence interval [CI] 0.63 to 1.82). Among 510 patients with severe CAD (>60% stenosis), allelic frequency was 32.0%, compared with 34.8% for 168 subjects without CAD (<10% stenosis, p = 0.33); 11.2% of patients with CAD compared with 13.1% of control subjects were homozygous (p = 0.50, OR 0.83, 95% CI 0.5 to 1.40). Conclusions. Patients with angiographic evidence of CAD or clinical MI do not show an increased frequency of the C677T transition in the MTHFR gene. Our findings do not support this polymorphism as risk factor for CAD or MI in predominantly white, well nourished population of unrestricted age.